ConductScience.org, home

Paper31335166

An Exploratory Analysis of Real-World End Points for Assessing Outcomes Among Immunotherapy-Treated Patients With Advanced Non-Small-Cell Lung Cancer.

Stewart M and 17 others. JCO Clin Cancer Inform, 2019. Cited by 101 papers, by iCite.

Cite this record

ConductScience Library. An Exploratory Analysis of Real-World End Points for Assessing Outcomes Among Immunotherapy-Treated Patients With Advanced Non-Small-Cell Lung Cancer. Papers, record 31335166. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/31335166

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
An Exploratory Analysis of Real-World End Points for Assessing Outcomes Among Immunotherapy-Treated Patients With Advanced Non-Small-Cell Lung Cancer.
PubMed
Journal
JCO Clin Cancer Inform
PubMed
Year
2019
PubMed
Publication types
Journal Article, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
101
iCite
Relative citation ratio, by iCite
3.14
iCite
Revised in PubMed
2021-04-29
PubMed

Authors18

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Stewart MMark
2Norden ADAndrew D
3Dreyer NNancy
4Henk HJHenry Joe
5Abernethy APAmy P
6Chrischilles EElizabeth
7Kushi LLawrence
8Mansfield ASAaron S
9Khozin SSean
10Sharon EElad
11Arunajadai SSrikesh
12Carnahan RRyan
13Christian JBJennifer B
14Miksad RARebecca A
15Sakoda LCLori C
16Torres AZAracelis Z
17Valice EEmily
18Allen JJeff

Source PubMed

Download CSV of authors

Topics18

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Carcinoma, Non-Small-Cell LungMajor topic
Lung NeoplasmsMajor topic
Adult
Aged
Aged, 80 and over
Antineoplastic Agents, Immunological
B7-H1 Antigen
Databases, Factual
Electronic Health Records
Female
Humans
Immunotherapy
Male
Middle Aged
Neoplasm Metastasis
Neoplasm Staging
Patient Outcome Assessment
United States

Source PubMed

Download CSV of topics

Grants4

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated bySource
K07 CA188142NCI NIH HHSUnited StatesK07CA188142PubMed and NIHNIH RePORTER
K12 CA090628NCI NIH HHSUnited StatesK12CA090628PubMed and NIHNIH RePORTER
P30 CA015083NCI NIH HHSUnited StatesP30CA015083PubMed and NIHNIH RePORTER
U24 CA171524NCI NIH HHSUnited StatesU24CA171524PubMed and NIHNIH RePORTER

Download CSV of grants

Trials1

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's record
NCT05700344SOGUG-AVELUMAB_RWDBackground

Source ClinicalTrials.gov

Download CSV of trials

Comments and corrections1

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

KindPMIDTitleIn Papers
Comment in31335165Practical Application of Real-World Evidence in Developing Cancer Therapies.https://conductscience.org/library/papers/31335165

Source PubMed

Download CSV of comments and corrections

References13

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
128836267When and How Can Real World Data Analyses Substitute for Randomized Controlled Trials?Clin Pharmacol Ther2017https://conductscience.org/library/papers/28836267PubMed
225848584The HMO Research Network Virtual Data Warehouse: A Public Data Model to Support Collaboration.EGEMS (Wash DC)2014https://conductscience.org/library/papers/25848584PubMed
330026923Real world evidence (RWE) - a disruptive innovation or the quiet evolution of medical evidence generation?F1000Res2018https://conductscience.org/library/papers/30026923PubMed
424504926Cancer recurrence: an important but missing variable in national cancer registries.Ann Surg Oncol2014https://conductscience.org/library/papers/24504926PubMed
527662202Blinatumomab vs historical standard therapy of adult relapsed/refractory acute lymphoblastic leukemia.Blood Cancer J2016https://conductscience.org/library/papers/27662202PubMed
629756355Development and Validation of a High-Quality Composite Real-World Mortality Endpoint.Health Serv Res2018https://conductscience.org/library/papers/29756355PubMed
729714575Advancing a Framework for Regulatory Use of Real-World Evidence: When Real Is Reliable.Ther Innov Regul Sci2018https://conductscience.org/library/papers/29714575PubMed
830105359Real-World Evidence and Real-World Data for Evaluating Drug Safety and Effectiveness.JAMA2018https://conductscience.org/library/papers/30105359PubMed
912663734End points and United States Food and Drug Administration approval of oncology drugs.J Clin Oncol2003https://conductscience.org/library/papers/12663734PubMed
1030873729An evaluation of the impact of missing deaths on overall survival analyses of advanced non-small cell lung cancer patients conducted in an electronic health records database.Pharmacoepidemiol Drug Saf2019https://conductscience.org/library/papers/30873729PubMed
1129423118The efficacy and safety of anti-PD-1/PD-L1 antibody therapy versus docetaxel for pretreated advanced NSCLC: a meta-analysis.Oncotarget2018https://conductscience.org/library/papers/29423118PubMed
1228529317How much do clinical trials cost?Nat Rev Drug Discov2017https://conductscience.org/library/papers/28529317PubMed
1328767357Evidence for Health Decision Making - Beyond Randomized, Controlled Trials.N Engl J Med2017https://conductscience.org/library/papers/28767357PubMed

Download CSV of references

Cited by81

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 101 citations.

PMIDTitleJournalYearIn PapersSource
42825071Early endocrine diagnoses and subsequent survival after immune checkpoint inhibitor initiation in non-small cell lung cancer: a 180-day landmark cohort study.Front Oncol2026https://conductscience.org/library/papers/42825071PubMed
42794628Androgen Receptor T878A and L702H Alterations Define Subsets of Prostate Cancer Patients with Distinct Outcomes to Androgen Receptor Pathway Inhibitors.Int J Mol Sci2026https://conductscience.org/library/papers/42794628PubMed
42601535Association between opioid use and treatment discontinuation in patients receiving nivolumab: a real-world database study.Support Care Cancer2026https://conductscience.org/library/papers/42601535PubMed
42563022The End of 'Pay-and-Hope': Managing Accelerated Approvals with Outcomes-Based Reimbursement in the Era of Routinely Collected Health Data.Pharmacoeconomics2026https://conductscience.org/library/papers/42563022PubMed
42004488Developing and evaluating definitions of real-world clinical endpoints for patients with early-stage triple-negative breast cancer using a United States of America secondary database.ESMO Real World Data Digit Oncol2026https://conductscience.org/library/papers/42004488PubMed
41843049Clinically Meaningful, Patient-Centered Endpoints for Real-World Evidence Generation in Breast Cancer: Perspectives from the Multidisciplinary TRIUMPH Initiative.Adv Ther2026https://conductscience.org/library/papers/41843049PubMed
41807852Time to Treatment Discontinuation and Cost Effectiveness of Third-Line Therapies in Advanced Colorectal Cancer: Real-World Evidence from the NIH All of Us Research Program.Drugs Real World Outcomes2026https://conductscience.org/library/papers/41807852PubMed
41593124Exploration of real-world outcomes in patients with previously treated HR+/HER2- and triple negative metastatic breast cancer.Sci Rep2026https://conductscience.org/library/papers/41593124PubMed
41450930Outcomes with frontline immune checkpoint inhibitors among individuals with BRAF-mutant non-small cell lung cancer.Front Oncol2025https://conductscience.org/library/papers/41450930PubMed
41390939The effect of common medications on the efficacy of immune checkpoint inhibitors.Cancer2025https://conductscience.org/library/papers/41390939PubMed
41277909Chemotherapy response monitoring with DNA methylation-based ctDNA tumor fraction: Evidence from a real-world cohort of patients with advanced common solid malignancies.J Liq Biopsy2025https://conductscience.org/library/papers/41277909PubMed
41201834Clinical and Genomic Factors Associated with Elacestrant Outcomes in ESR1-Mutant Metastatic Breast Cancer.Clin Cancer Res2026https://conductscience.org/library/papers/41201834PubMed
40884222Real-world costs, treatment patterns, and clinical outcomes associated with treatments for advanced anaplastic lymphoma kinase-positive non-small cell lung cancer.J Manag Care Spec Pharm2025https://conductscience.org/library/papers/40884222PubMed
40354012Real-World Evidence Acceptability and Use in Breast Cancer Treatment Decision-Making in the United States: Call-to-Action from a Multidisciplinary Think Tank.Adv Ther2025https://conductscience.org/library/papers/40354012PubMed
39819032Real-world ePRO use and clinical outcomes using electronic patient-reported symptom monitoring for patients with advanced non-small-cell lung cancer receiving first-line pembrolizumab.J Comp Eff Res2025https://conductscience.org/library/papers/39819032PubMed
39551068Effectiveness and safety of immune checkpoint inhibitors in Black patients versus White patients in a US national health system: a retrospective cohort study.Lancet Oncol2024https://conductscience.org/library/papers/39551068PubMed
39365963Development and Portability of a Text Mining Algorithm for Capturing Disease Progression in Electronic Health Records of Patients With Stage IV Non-Small Cell Lung Cancer.JCO Clin Cancer Inform2024https://conductscience.org/library/papers/39365963PubMed
39146509Evaluation of Real-World Tumor Response Derived From Electronic Health Record Data Sources: A Feasibility Analysis in Patients With Metastatic Non-Small Cell Lung Cancer Treated With Chemotherapy.JCO Clin Cancer Inform2024https://conductscience.org/library/papers/39146509PubMed
39113428Exploring the discrepancies between clinical trials and real-world data: A small-cell lung cancer study.Clin Transl Sci2024https://conductscience.org/library/papers/39113428PubMed
39102176Examining the Effect of Missing Data and Unmeasured Confounding on External Comparator Studies: Case Studies and Simulations.Drug Saf2024https://conductscience.org/library/papers/39102176PubMed

See all 81 cited byDownload CSV of cited by

Genes3

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
ALK238PubTator's text mininghttps://conductscience.org/library/genes/238NCBI Gene
CD27429126PubTator's text mininghttps://conductscience.org/library/genes/29126NCBI Gene
EGFR1956PubTator's text mininghttps://conductscience.org/library/genes/1956NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/31335166

GET https://conductscience.org/api/papers/v1/31335166/cited_by?page=2